[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"EyeBiotech Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100631122","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-003-100631122",false,"NCT07496567","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-003)","A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2\u002F3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201\u002FMK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)","TORRONTES","The main inclusion criteria include but are not limited to the following:\n\n* Has treatment naive choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) including subfoveal, juxtafoveal and extrafoveal lesions or retinal angiomatous proliferations (RAP) and polypoidal choroidal vascularization (PCV) lesions in at least one eye (study eye)\n* The diagnosis of neovascular age-related macular degeneration (NVAMD) must have been made within 21 days prior to starting study treatment\n\nThe main exclusion criteria include but are not limited to the following\n\n* Has uncontrolled blood pressure at screening\n* History of any prior macular laser photocoagulation in the study eye\n* History of uveitis in either eye\n* History of cataract surgery, minimally invasive glaucoma surgery, or Yttrium-Aluminium Garnet (Yag) laser capsulotomy in the study eye within 90 days before entering the study\n* Has uncontrolled glaucoma in the study eye\n* Active retinal disease other than the condition under investigation in the study eye\n* Has previously received anti- vascular endothelial growth factor (VEGF) therapy or other intravitreal (IVT) therapy in the study eye","ALL","50 Years",{"count":20,"type":21},960,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD).\n\nAvailable standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD.\n\nThe goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.",[28,29,30,31],"Macular Degeneration","Age-Related Macular Degeneration","Choroidal Neovascularization","Wet Macular Degeneration","RECRUITING","2026-06-27",{"date":35,"type":36},"2026-06-30","ACTUAL",{"date":38,"type":36},"2026-04-15",{"date":40,"type":21},"2028-07-31",{"name":42,"class":43},"EyeBiotech Ltd.","INDUSTRY",48,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":14,"acronym":50,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":26,"conditions":53,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":54,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":60},"100626791","phase-2-a-clinical-trial-of-eye201mk-8748-in-people-with-macular-degeneration-mk-8748-002-100626791","NCT07440225","A Clinical Trial of EYE201\u002FMK-8748 in People With Macular Degeneration (MK-8748-002)","MALBEC",{"count":20,"type":21},[24,25],[28,29,30,31],{"date":35,"type":36},{"date":56,"type":36},"2026-03-27",{"date":58,"type":21},"2028-06-30",{"name":42,"class":43},71,{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":17,"minAge":69,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":22,"phases":72,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":88,"locationsCount":89},"100608771","phase-2-a-dose-masked-study-of-intravitreal-eye103-in-participants-with-nvamd-or-macular-edema-following-brvo-100608771","NCT07205887","A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO","A Phase 2 Randomized, Dose-Masked Study of Intravitreal EYE103 in Participants With Neovascular Age-Related Macular Degeneration (NVAMD) or Macular Edema Following Branch Retinal Vein Occlusion (BRVO)","Super Tuscan","Inclusion Criteria:\n\nKey General Inclusion Criteria\n\n• Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity\n\nKey Neovascular Age-related Macular Degeneration (NVAMD)-specific Inclusion Criteria\n\n* Be ≥ 50 years of age\n* Have treatment naive subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) or juxtafoveal\u002Fextrafoveal CNV with foveal involvement\n* For participants who are treatment naïve for NVAMD, the diagnosis must have been made within 21 days prior to the Day 1 study treatment\n\nKey Incomplete Responder (IR) NVAMD-specific Inclusion Criteria\n\n* Be ≥ 50 years of age\n* Have subfoveal CNV secondary to AMD or juxtafoveal\u002Fextrafoveal CNV with foveal involvement at initial screening\n* For participants who are treatment experienced for NVAMD, the diagnosis must have been made within 90 days prior to the Screening Visit 2\n\nKey Branch Retinal Vein Occlusion (BRVO)-specific Inclusion Criteria\n\n* Be diagnosed with BRVO in the study eye\n* Have a decrease in vision in the study eye determined by the Investigator to be primarily the result of BRVO\n* Be treatment naïve with vision loss in the study eye and have center-involving macular edema diagnosed within 9 months of Screening\n\nExclusion Criteria:\n\nKey General Exclusion Criteria\n\n* Pregnant or breastfeeding\n* History of cataract surgery and\u002For minimally invasive glaucoma surgery in the study eye within 90 days of Screening\n* Have had Yttrium-Aluminum Garnet (YAG) laser capsulotomy in the study eye within 90 days of Screening\n* Currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)\n\nKey NVAMD-specific Exclusion Criteria\n\n* Have had previous thermal subfoveal laser therapy in the study eye\n* Have had previous photodynamic therapy with Visudyne in the study eye\n\nKey BRVO-specific Exclusion Criteria\n\n* Have macular edema in the study eye considered to be secondary to a cause other than BRVO (eg, diabetic macular edema, NVAMD, Irvine-Gass syndrome)\n* Have active iris or angle neovascularization or neovascular glaucoma in the study eye","18 Years",{"count":71,"type":21},160,[24],"EYE-RES-104 is a randomized, dose-masked study of intravitreal EYE103 in participants with neovascular age-related macular degeneration (NVAMD) or macular edema following branch retinal vein occlusion (BRVO).\n\nThe study will consist of 4 patient cohorts, with participants in each cohort randomized (1:1) to either a low dose of EYE103 via IVT or a high dose of EYE103 via IVT. 40 participants will be enrolled in each cohort. Enrollment timing for each cohort will be sequenced into specific arms of the study at the Sponsor's discretion.\n\nAll participants in the study will receive a total of 3 injections of EYE103 into the study eye, spaced at 4 weeks apart. All participants will return at designated time points following each injection for safety and efficacy assessments. The Week 12 Visit will serve as the end of study visit for all participants.",[75,76],"Neovascular Age-Related Macular Degeneration (NVAMD)","Branch Retinal Vein Occlusion (BRVO)",[78,79,80,81],"Neovascular Age-Related Macular Degeneration","Branch Retinal Vein Occlusion","NVAMD","BRVO","2026-06-16",{"date":84,"type":36},"2026-06-18",{"date":86,"type":36},"2025-09-12",{"date":58,"type":21},{"name":42,"class":43},49,""]